Navigation Links
Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
Date:9/30/2013

that tumor-cell associated HA may be a better predictor of PEGPH20 combination treatment effect compared to stromal associated HA.

Treatment was generally well tolerated, and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. The most common adverse events for PEGPH20 were muscle spasms, myalgia and arthralgia (all grade 1/2). There was no evidence of new toxicities when used in combination with gemcitabine and the pharmacokinetics of PEGPH20 with gemcitabine was consistent with the pharmacokinetics of PEGPH20 as a single agent. Additionally, the pharmacodynamic and pharmacokinetics results support the dosing regimen of PEGPH20 at 3µg/kg, which is being used in an on-going Phase 2 trial.

Halozyme has initiated a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 in combination with nab-paclitaxel and gemcitabine to confirm the combination treatment effect (ORR, PFS and OS) based on HA levels. The study plans to enroll approximately 124 patients with stage IV pancreatic ductal adenocarcinoma. Halozyme is also developing an HA diagnostic tool to be used in this study to evaluate the potential treatment benefit based on tumor HA levels at baseline. This diagnostic approach may enable additional PEGPH20 combination clinical studies in other HA-rich tumor types.

About PEGPH20

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 has been shown to deplete this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render the tumor more vulnerable to therapy as well as inhibit tumor growth.

About Pancreatic Cancer

In most patients diagnosed with metastatic pancreatic adenocarcinoma, survival rates are the low
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
2. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
3. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
4. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
5. Halozyme Reports Second Quarter 2013 Financial Results
6. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
7. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
8. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
9. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
10. Halozyme Reports First Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... ("IVD") company, today announced that it has received approvals ... 2-alpha ("TOP2A") FISH detection kit from the State Food ... of China. The Company has received ...
... YASOO Health Inc, Morrisville, NC has introduced IronUp, ... levels of dietary iron for infants and children who ... www.yasooproducts.com/ironup ). (Photo: http://photos.prnewswire.com/prnh/20110810/CL49882 ) ... liquid iron supplement from a bioavailable source of iron ...
Cached Medicine Technology:China Medical Technologies Announces SFDA Approvals for its Prostate Cancer FISH Detection Kit and TOP2A FISH Detection Kit 2China Medical Technologies Announces SFDA Approvals for its Prostate Cancer FISH Detection Kit and TOP2A FISH Detection Kit 3YASOO Health Introduces IronUp™ 2
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... released a new blog post explaining the importance of keeping a ... of an auto insurance policy . , Clients who driver ... their vehicle insurance policies. The safety a vehicle offers from its ... of this, drivers should always carry a first aid kit in ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Dec. 7 (HealthDay News) -- Positive family attitudes and ... reduce their risk of depression, substance abuse and suicidal ... finds. The study authors also found that those ... of self-esteem and social support when they,re young adults. ...
... a way to isolate neural stem cells cells that ... from human brain tissue with unprecedented precision, an important ... system, like Parkinson,s and Huntington,s diseases and spinal cord injury. ... the University of Rochester Medical Center was published in the ...
... public health concerns about increasing antiviral resistance among certain ... of alternative antiviral treatment options. The findings are published ... of Infectious Diseases . (Please see below for links ... with two classes of drugs: M2 blockers (adamantanes) and ...
... Randy Dotinga HealthDay Reporter , MONDAY, Dec. 6 (HealthDay ... an end to sex, according to an Australian study. The ... sexually active at least once a year -- including about 1 ... older men who are sexually active say they,d love to be ...
... of making, distributing and administering millions of seasonal ... design a vaccine that confers decades-long protection from ... influenza vaccine is feasible but licensing it may ... ways to evaluate the efficacy of vaccine candidates ...
... MONDAY, Dec. 6 (HealthDay News) -- A new study finds ... risk for high blood pressure, which is a major risk ... disease and stroke in the United States decreased 65 percent ... are still higher in the southeastern United States, in blacks ...
Cached Medicine News:Health News:Parents' Acceptance May Help Protect Gay Teens 2Health News:Stem cell advance a step forward for treatment of brain diseases 2Health News:Stem cell advance a step forward for treatment of brain diseases 3Health News:Influenza virus strains show increasing drug resistance and ability to spread 2Health News:Influenza virus strains show increasing drug resistance and ability to spread 3Health News:Many Men Over 75 Still Sexually Active: Study 2Health News:Many Men Over 75 Still Sexually Active: Study 3Health News:A flu vaccine that lasts 2Health News:Race, Gender Play Part in Hypertension Risk 2
Dilator...
Microscopic scissors, curved...
Microscopic needle holder, curved...
... Back discomfort is a complaint ... wear our most comfortable apron. ... weight off the shoulders and ... shoulder pads are standard for ...
Medicine Products: